Denis Devenport, MD
Psychiatry · la Place, LANPI 1588724124
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 350 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 22.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,970, 2.7 times the $725 reported in 2019. Among psychiatry clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 350 payments — averaging $17.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Otsuka America Pharmaceutical, Inc.$847
- Alkermes, Inc.$761
- Neurocrine Biosciences, Inc.$580
- Johnson & Johnson$445
- Indivior Inc.$368
- plus $2K from 13 others
What the payments were for
- Food & beverage$5,998100%
- Education$280%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 113 | $1,339 |
| Otsuka America Pharmaceutical, Inc. | 45 | $847 |
| Alkermes, Inc. | 43 | $761 |
| Neurocrine Biosciences, Inc. | 22 | $580 |
| Johnson & Johnson | 23 | $445 |
| Indivior Inc. | 16 | $368 |
| Vanda Pharmaceuticals Inc. | 16 | $340 |
| Sunovion Pharmaceuticals Inc. | 16 | $272 |
| E.r. Squibb & Sons, L.L.C. | 13 | $218 |
| Axsome Therapeutics, Inc. | 11 | $216 |
| Supernus Pharmaceuticals, Inc. | 5 | $173 |
| Teva Pharmaceuticals USA, Inc. | 10 | $170 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $96 |
| Lundbeck LLC | 5 | $84 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $41 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $23 |
| Corium, LLC | 1 | $21 |
| Braeburn Inc. | 1 | $18 |
| Luye Pharma (USA) Ltd. | 1 | $15 |
How this compares
$6,026 in reported general payments places this provider in the 90th percentile of 474 psychiatry providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 200 | $574,317 |
| Invega TrinzaPaliperidone Palmitate | 19 | $169,624 |
| VraylarCariprazine Hcl | 94 | $137,813 |
| AristadaAripiprazole Lauroxil | 27 | $82,595 |
| Lurasidone Hcl | 149 | $37,033 |
| Abilify MaintenaAripiprazole | 13 | $30,965 |
| FanaptIloperidone | 19 | $24,977 |
| Ziprasidone Hcl | 143 | $7,567 |
| Asenapine Maleate | 37 | $6,155 |
| Quetiapine Fumarate | 390 | $5,593 |
| Duloxetine Hcl | 325 | $5,314 |
| Olanzapine | 226 | $4,402 |
| Amitriptyline Hcl | 187 | $4,220 |
| Mirtazapine | 369 | $3,846 |
| Trazodone Hcl | 443 | $3,361 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $445 | $743,941219 claims |
| AbbVieVraylar | $1,339 | $137,81394 claims |
| Alkermes, Inc.Aristada | $761 | $82,59527 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $847 | $30,96513 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $340 | $24,97719 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 474 psychiatry providers in Louisiana.
Other psychiatry in la Place
- Brennen Watsonla Place$5K
- Patrick HayesLake Charles$837K
- Maria CruseThibodaux$522K
- Larry WarnerBaton Rouge$495K
- Gregory BrownShreveport$495K
- Arwen PodestaNew Orleans$466K
- Jasjit SinghShreveport$420K
- Roger BrownMandeville$216K
- Abdul KhanBaton Rouge$156K
- William ColombMandeville$117K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.